Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

High IGF2 and FGFR3 are associated with tumour progression in undifferentiated pleomorphic sarcomas, but EGFR and FGFR3 mutations are a rare event.

Rüping K, Altendorf-Hofmann A, Chen Y, Kampmann E, Gibis S, Lindner L, Katenkamp D, Petersen I, Knösel T.

J Cancer Res Clin Oncol. 2014 Aug;140(8):1315-22. doi: 10.1007/s00432-014-1700-9. Epub 2014 May 8.

PMID:
24804818
2.

Loss of p16(INK4a) is associated with reduced patient survival in soft tissue tumours, and indicates a senescence barrier.

Knösel T, Altendorf-Hofmann A, Lindner L, Issels R, Hermeking H, Schuebbe G, Gibis S, Siemens H, Kampmann E, Kirchner T.

J Clin Pathol. 2014 Jul;67(7):592-8. doi: 10.1136/jclinpath-2013-202106. Epub 2014 Apr 19.

PMID:
24747207
3.

Epithelioid sarcoma expresses epidermal growth factor receptor but gene amplification and kinase domain mutations are rare.

Cascio MJ, O'Donnell RJ, Horvai AE.

Mod Pathol. 2010 Apr;23(4):574-80. doi: 10.1038/modpathol.2010.2. Epub 2010 Jan 29.

4.
5.

TLE1 is a robust diagnostic biomarker for synovial sarcomas and correlates with t(X;18): analysis of 319 cases.

Knösel T, Heretsch S, Altendorf-Hofmann A, Richter P, Katenkamp K, Katenkamp D, Berndt A, Petersen I.

Eur J Cancer. 2010 Apr;46(6):1170-6. doi: 10.1016/j.ejca.2010.01.032. Epub 2010 Feb 25.

PMID:
20189377
6.

Expression of insulin-like growth factor 2 in mesenchymal neoplasms.

Steigen SE, Schaeffer DF, West RB, Nielsen TO.

Mod Pathol. 2009 Jul;22(7):914-21. doi: 10.1038/modpathol.2009.48. Epub 2009 May 1.

7.

IGF2 is highly expressed in pediatric undifferentiated sarcomas and reveals two distinct cytoplasmic trafficking patterns.

Somers GR, Ho M, Pienkowska M, Shlien A, Malkin D, Ackerley C, Zielenska M.

Pediatr Dev Pathol. 2010 May-Jun;13(3):169-77. doi: 10.2350/09-02-0613-OA.1.

PMID:
19586133
8.

Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma.

Thomas DG, Giordano TJ, Sanders D, Biermann S, Sondak VK, Trent JC, Yu D, Pollock RE, Baker L.

Cancer. 2005 Feb 15;103(4):830-8.

9.

TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities.

Koelsche C, Renner M, Hartmann W, Brandt R, Lehner B, Waldburger N, Alldinger I, Schmitt T, Egerer G, Penzel R, Wardelmann E, Schirmacher P, von Deimling A, Mechtersheimer G.

J Exp Clin Cancer Res. 2014 Apr 11;33:33. doi: 10.1186/1756-9966-33-33.

10.

VEGFR2 predicts decreased patients survival in soft tissue sarcomas.

Kampmann E, Altendorf-Hofmann A, Gibis S, Lindner LH, Issels R, Kirchner T, Knösel T.

Pathol Res Pract. 2015 Oct;211(10):726-30. doi: 10.1016/j.prp.2015.04.015. Epub 2015 May 21.

PMID:
26298629
11.
12.

Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP Study Group. Chromosomes and MorPhology.

Mertens F, Fletcher CD, Dal Cin P, De Wever I, Mandahl N, Mitelman F, Rosai J, Rydholm A, Sciot R, Tallini G, Van den Berghe H, Vanni R, Willén H.

Genes Chromosomes Cancer. 1998 May;22(1):16-25.

PMID:
9591630
13.

Prognostic value of myogenic differentiation in undifferentiated pleomorphic sarcomas of soft tissue.

Cipriani NA, Kurzawa P, Ahmad RA, Deshpande V, Hornicek FJ, Mullen JT, Nielsen GP.

Hum Pathol. 2014 Jul;45(7):1504-8. doi: 10.1016/j.humpath.2014.03.002. Epub 2014 Mar 26.

PMID:
24780826
14.

TGFBR3 and MGEA5 rearrangements are much more common in "hybrid" hemosiderotic fibrolipomatous tumor-myxoinflammatory fibroblastic sarcomas than in classical myxoinflammatory fibroblastic sarcomas: a morphological and fluorescence in situ hybridization study.

Zreik RT, Carter JM, Sukov WR, Ahrens WA, Fritchie KJ, Montgomery EA, Weiss SW, Folpe AL.

Hum Pathol. 2016 Jul;53:14-24. doi: 10.1016/j.humpath.2016.02.005. Epub 2016 Mar 2.

PMID:
26980036
15.

Histopathological re-classification of extremity pleomorphic soft tissue sarcoma has clinical relevance.

Massi D, Beltrami G, Capanna R, Franchi A.

Eur J Surg Oncol. 2004 Dec;30(10):1131-6.

PMID:
15522563
16.

Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer.

Fischbach A, Rogler A, Erber R, Stoehr R, Poulsom R, Heidenreich A, Schneevoigt BS, Hauke S, Hartmann A, Knuechel R, Veeck J, Gaisa NT.

Histopathology. 2015 Apr;66(5):639-49. doi: 10.1111/his.12473. Epub 2015 Jan 12.

PMID:
24898159
17.

Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas.

Kersting C, Packeisen J, Leidinger B, Brandt B, von Wasielewski R, Winkelmann W, van Diest PJ, Gosheger G, Buerger H.

J Clin Pathol. 2006 Jun;59(6):585-90. Epub 2006 Feb 3.

18.

Investigation of IGF2, Hedgehog and fusion gene expression profiles in pediatric sarcomas.

de Souza RR, Oliveira ID, del Giúdice Paniago M, Yaoita FH, Caran EM, Macedo CR, Petrilli AS, Abib Sde C, de Seixas Alves MT, de Toledo SR.

Growth Horm IGF Res. 2014 Aug;24(4):130-6. doi: 10.1016/j.ghir.2014.04.002. Epub 2014 Apr 16.

PMID:
24846856
19.

Expression of insulin-like growth factor mitogenic signals in adult soft-tissue sarcomas: significant correlation with malignant potential.

Busund LT, Ow KT, Russell P, Crowe PJ, Yang JL.

Virchows Arch. 2004 Feb;444(2):142-8. Epub 2003 Dec 12.

PMID:
14673647
20.

Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas.

Tamborini E, Casieri P, Miselli F, Orsenigo M, Negri T, Piacenza C, Stacchiotti S, Gronchi A, Pastorino U, Pierotti MA, Pilotti S.

J Pathol. 2007 Jun;212(2):227-35.

PMID:
17471466

Supplemental Content

Support Center